FDA reviews the use of progression-free survival in cancer trials
from Medscape Medical News
A faster, less expensive method of verifying progression-free survival data in cancer drug clinical trials is being considered by the U.S. Food and Drug Administration. But the potential change in methodology is seen as a threat to quality data by a number of experts. The matter was debated at an unusual meeting of the FDA Oncologic Drugs Advisory Committee.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063